anti-fucosylated antigen antibody
Springer Online Journal Archives 1860-2000
Chemistry and Pharmacology
Abstract A newly generated monoclonal antibody, YB-2, reacts simultaneously with Y (Fucα1→2Galβ1→4[Fucα1→3]GlcNAcβ), Leb (fucα1→2Galβ1→3[Fucα1→4]GlcNAcβ) and H type 2 (Fucα1→2Galβ1→4GlcNAcβ) antigens (Jpn J Cancer Res 1993: 84; 641-8). Since these antigens have been reported to be expressed strongly in malignant colorectal tissues, we investigated the usefulness of this antibody as an immunochemical tool for diagnosis of colorectal cancer. The rate of positive staining with YB-2 antibody in colorectal carcinoma (n=101), adenoma (n=26) and normal tissues (n=25) was 95.0, 50.0 and 12.0%, respectively. The specimens with negative staining were restricted in Dukes' A patients but 75% of Dukes' C patients were strongly positive. The intensity of positive staining with YB-2 antibody was also significantly related to the clinico-pathological features such as the depth of invasion, metastasis, histological types and tumor location. Moreover, the 5-year survival in patients whose tumors were positive with YB-2 antibody was found to be significantly low. Therefore, YB-2 antibody could be useful for immunodiagnosis and, possibly, immunotherapy of colorectal carcinoma.
Type of Medium: